arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SCYNEXIS INC

SCYX
$4.66 ▼ -0.18 (-3.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

SCYNEXIS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $29.1M
Dividend Yield —
Revenue Growth 449.9% ↗
Op. Margin -78.0%
ROIC -32.6% ↗
FCF / Share $-0.85 ↗
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.60M
↑ +449.9% —
Net Income Profit after all expenses
$-8.61M
↑ +59.6% —
Operating Margin Operating profit as % of sales
-78.0%
↓ -250.5% 3th
FCF / Share Free cash flow per share
$-0.85
↑ +78.6% —
Long-Term Debt Long-term obligations
$34.39M
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
6
Returns ↑
29
Financial Health ↓
19
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 55 quarters